Citations (202)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (27)
Wenbing Zhang, Jian Ding, Wenhai Wang, Duo Wang, Yinping Pan & Dexin Xu. (2023) Status and Future Directions of Therapeutics and Prognosis of Cardiac Amyloidosis. Therapeutics and Clinical Risk Management 19, pages 581-597.
Read now
Read now
Felix J. Tsai, Luke T. Nelson, Gabriel M. Kline, Marcus Jäger, John L. Berk, Yoshiki Sekijima, Evan T. Powers & Jeffery W. Kelly. (2023) Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange. Amyloid 30:2, pages 220-224.
Read now
Read now
David A. Tess, Tristan S. Maurer, Zhenhong Li, Christine Bulawa, James Fleming & Amy T. Moody. (2023) Relationship of binding-site occupancy, transthyretin stabilisation and disease modification in patients with tafamidis-treated transthyretin amyloid cardiomyopathy. Amyloid 30:2, pages 208-219.
Read now
Read now
Cecília Monteiro, Jaleh S. Mesgarzadeh, João Anselmo, Joana Fernandes, Marta Novais, Carla Rodrigues, David L. Powers, Evan T. Powers, Teresa Coelho & Jeffery W. Kelly. (2023) Tafamidis polyneuropathy amelioration requires modest increases in transthyretin stability even though increases in plasma native TTR and decreases in non-native TTR do not predict response. Amyloid 30:1, pages 81-95.
Read now
Read now
Yusuke Takahashi, Nobuhiko Ohashi, Ken Takasone, Tsuneaki Yoshinaga, Masahide Yazaki, Michael Roberts, Paul F. Glidden & Yoshiki Sekijima. (2022) CSF/plasma levels, transthyretin stabilisation and safety of multiple doses of tolcapone in subjects with hereditary ATTR amyloidosis. Amyloid 29:3, pages 190-196.
Read now
Read now
Arianna Burton, Adam Castaño, Marianna Bruno, Steve Riley, Jennifer Schumacher, Marla B Sultan, Sandi See Tai, Daniel P Judge, Jignesh K Patel & Jeffery W Kelly. (2021) Drug Discovery and Development in Rare Diseases: Taking a Closer Look at the Tafamidis Story. Drug Design, Development and Therapy 15, pages 1225-1243.
Read now
Read now
R. Spoladore, G. Falasconi, M. Marcatti, S. Di Maio, G. Fiore, M. Slavich, A. Margonato, A. Turco & G. Fragasso. (2021) Advances in pharmacotherapy for cardiac amyloidosis. Expert Opinion on Pharmacotherapy 22:4, pages 469-481.
Read now
Read now
Luke T. Nelson, Ryan J. Paxman, Jin Xu, Bill Webb, Evan T. Powers & Jeffery W. Kelly. (2021) Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma. Amyloid 28:1, pages 24-29.
Read now
Read now
Xiaohua Guo, Zhaowen Liu, Yizhou Zheng, Yamei Li, Linfu Li, Hai Liu, Zhixi Chen & Longhuo Wu. (2020) Review on the Structures and Activities of Transthyretin Amyloidogenesis Inhibitors. Drug Design, Development and Therapy 14, pages 1057-1081.
Read now
Read now
Veena Mathew & Annabel K Wang. (2019) Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis. Drug Design, Development and Therapy 13, pages 1515-1525.
Read now
Read now
Prakash Harikrishnan, Srikanth Yandrapalli, Wilbert S. Aronow, Gregg M. Lanier & Diwakar Jain. (2019) Novel drug therapies for cardiac amyloidosis. Expert Opinion on Investigational Drugs 28:6, pages 497-499.
Read now
Read now
Joel N. Buxbaum. (2019) Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: the role of randomized controlled trials. Amyloid 26:2, pages 55-65.
Read now
Read now
Asad Ikram, Joseph P. Donnelly, Brett W. Sperry, Christy Samaras, Jason Valent & Mazen Hanna. (2018) Diflunisal tolerability in transthyretin cardiac amyloidosis: a single center’s experience. Amyloid 25:3, pages 197-202.
Read now
Read now
Hirofumi Jono & Yukio Ando. (2017) Towards targets and treatments in transthyretin amyloidosis. Expert Opinion on Orphan Drugs 5:9, pages 691-699.
Read now
Read now
Sayaka Matsumoto, Mitsuharu Ueda, Taro Yamashita, Tomoko Amano, Yohei Misumi, Masayoshi Tasaki, Teruaki Masuda, Mayumi Mizukami, Hirokazu Furuya & Yukio Ando. (2017) A late-onset case of hereditary transthyretin amyloidosis with a novel compound heterozygous mutation. Amyloid 24:sup1, pages 97-98.
Read now
Read now
Lixia Qiang, Yanxia Guan, Xiangshun Li, Li Liu, Yanshuang Mu, Aki Sugano, Yutaka Takaoka, Toshiyuki Sakaeda, Bruno P. Imbimbo, Ken-Ichi Yamamura, Shoude Jin & Zhenghua Li. (2017) CSP-1103 (CHF5074) stabilizes human transthyretin in healthy human subjects. Amyloid 24:1, pages 42-51.
Read now
Read now
Lidia Ciccone, Susanna Nencetti, Armando Rossello, Livia Tepshi, Enrico A. Stura & Elisabetta Orlandini. (2016) X-ray crystal structure and activity of fluorenyl-based compounds as transthyretin fibrillogenesis inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry 31:5, pages 824-833.
Read now
Read now
Philip N. Hawkins, Yukio Ando, Angela Dispenzeri, Alejandra Gonzalez-Duarte, David Adams & Ole B. Suhr. (2015) Evolving landscape in the management of transthyretin amyloidosis. Annals of Medicine 47:8, pages 625-638.
Read now
Read now
Giovanni Palladini, Paolo Milani & Giampaolo Merlini. (2015) Novel strategies for the diagnosis and treatment of cardiac amyloidosis. Expert Review of Cardiovascular Therapy 13:11, pages 1195-1211.
Read now
Read now
Yoshiki Sekijima, Kana Tojo, Hiroshi Morita, Jun Koyama & Shu-ichi Ikeda. (2015) Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis. Amyloid 22:2, pages 79-83.
Read now
Read now
Laura Obici & Giampaolo Merlini. (2014) An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis. Expert Opinion on Investigational Drugs 23:9, pages 1239-1251.
Read now
Read now
Michitaka Nakagawa, Yoshiki Sekijima, Kana Tojo & Shu-Ichi Ikeda. (2013) High prevalence of ATTR amyloidosis in endomyocardial biopsy-proven cardiac amyloidosis patients. Amyloid 20:2, pages 138-140.
Read now
Read now
John L. Berk, Ole B. Suhr, Yoshiki Sekijima, Taro Yamashita, Michael Heneghan, Steven R. Zeldenrust, Yukio Ando, Shu-ichi Ikeda, Peter Gorevic, Giampaolo Merlini, Jeffrey W. Kelly, Martha Skinner, Alice B. Bisbee, Peter J. Dyck & Laura Obici. (2012) The Diflunisal Trial: Study accrual and drug tolerance. Amyloid 19:sup1, pages 37-38.
Read now
Read now
Adam Castaño, Sabahat Bokhari, Thomas H. Brannagan$suffix/text()$suffix/text(), Julia Wynn & Mathew S. Maurer. (2012) Technetium pyrophosphate myocardial uptake and peripheral neuropathy in a rare variant of familial transthyretin (TTR) amyloidosis (Ser23Asn): a case report and literature review. Amyloid 19:1, pages 41-46.
Read now
Read now
J. L. Berk, P. J. Dyck, L. Obici, S. R. Zeldenrust, Y. Sekijima, T. Yamashita, Y. Ando, S.-I. Ikeda, P. Gorevic, G. Merlini, J. W. Kelly, M. Skinner, A. B. Bisbee & O. B. Suhr. (2011) The diflunisal trial: update on study drug tolerance and disease progression. Amyloid 18:sup1, pages 196-197.
Read now
Read now
Chloe M. Mak, Yok-Lam Kwong, Ching-Wan Lam, See-Ching Chan, Chung-Mau Lo, Sheung-Tak Fan, Chee-My Chang, Yuk-Kwong Lau, Lok-Sun U & Sidney Tam. (2007) Identification of a novel TTR Gly67Glu mutant and the first case series of familial transthyretin amyloidosis in Hong Kong Chinese. Amyloid 14:4, pages 293-297.
Read now
Read now
Articles from other publishers (175)
Michael A. Smith & Neil G. Feinglass. (2024) Perioperative implications of amyloidosis and amyloid cardiomyopathy: A review for anesthesiologists. Journal of Clinical Anesthesia 92, pages 111271.
Crossref
Crossref
Teresa Coelho, Wilson MarquesJrJr, Noel R. Dasgupta, Chi-Chao Chao, Yeşim Parman, Marcondes Cavalcante FrançaJrJr, Yuh-Cherng Guo, Jonas Wixner, Long-Sun Ro, Cristian R. Calandra, Pedro A. Kowacs, John L. Berk, Laura Obici, Fabio A. Barroso, Markus Weiler, Isabel Conceição, Shiangtung W. Jung, Gustavo Buchele, Michela Brambatti, Jersey Chen, Steven G. Hughes, Eugene Schneider, Nicholas J. Viney, Ahmad Masri, Morie R. Gertz, Yukio Ando, Julian D. Gillmore, Sami Khella, P. James B. Dyck, Márcia Waddington Cruz, Anna Mazzeo, Aikaterini Papagianni, Mazen Dimachkie, Ioannis Zaganas, Edward Gane, Marco Luigetti, Lucia Galan Davila, Michelle Mezei, Juan Gonzalez Moreno, Pascal Cintas, Davide Pareyson, Rebecca Traub, Julie Khoury, Conrado Estol, Merrilee Needham, David Adams, Michael Polydefkis, Thomas BrannaganIIIIII, Vera Bril, Shahram Attarian, Marcelo Rugiero, Barbara Distad, Eleni Zamba Papanicolaou, Kon-Ping Lin, Merrill Benson & Morton Scheinberg. (2023) Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy. JAMA 330:15, pages 1448.
Crossref
Crossref
Neasa Starr, Adam Ioannou & Ana Martinez-Naharro. (2023) Monitorización de la amiloidosis cardiaca con imagen multimodal. Revista Española de Cardiología.
Crossref
Crossref
Mineyuki Mizuguchi, Takeshi Yokoyama, Takuya Okada, Yusuke Nakagawa, Kanako Fujii, Yuko Nabeshima & Naoki Toyooka. (2023) Benziodarone and 6-hydroxybenziodarone are potent and selective inhibitors of transthyretin amyloidogenesis. Bioorganic & Medicinal Chemistry 90, pages 117370.
Crossref
Crossref
Paolo Morfino, Alberto Aimo, Giuseppe Vergaro, Chiara Sanguinetti, Vincenzo Castiglione, Maria Franzini, Marco Alfonso Perrone & Michele Emdin. (2023) Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy. Pharmaceutics 15:4, pages 1129.
Crossref
Crossref
L. Silva-Hernández, A. Horga Hernández, A. Valls Carbó, A. Guerrero Sola, M.T. Montalvo-Moraleda & L. Galán Dávila. (2023) Red flags in patients with hereditary transthyretin amyloidosis at diagnosis in a non-endemic area of Spain. Neurología (English Edition) 38:2, pages 87-92.
Crossref
Crossref
L. Silva-Hernández, A. Horga Hernández, A. Valls Carbó, A. Guerrero Sola, M.T. Montalvo-Moraleda & L. Galán Dávila. (2023) «Red flags» en pacientes con polineuropatía amiloidótica familiar relacionada con transtiretina (hATTR) en el momento del diagnóstico en un área no endémica de España. Neurología 38:2, pages 87-92.
Crossref
Crossref
Qunchao Ma, Mengdie Wang, Yanan Huang, Ying Nie, Xin Zhang, Dan Dan Yang, Zhuo Wang, Siyin Ding, Ningjing Qian, Yu Liu & Xiaohong Pan. (2023) Identification of a novel transthyretin mutation D39Y in a cardiac amyloidosis patient and its biochemical characterizations. Frontiers in Cardiovascular Medicine 10.
Crossref
Crossref
Thomas Zegkos, Thomas Gossios, Dimitris Ntelios, Despoina Parcharidou, Haralampos Karvounis & Georgios Efthimiadis. (2021) Wild-Type Transthyretin Amyloid Cardiomyopathy: The Gordian-Knot of Novel Therapeutic Regimens. Cardiology in Review 31:1, pages 36-41.
Crossref
Crossref
Fabio Mastrocola, Frank Nunes & Paulo Sgobbi. 2023. Amyloidosis and Fabry Disease. Amyloidosis and Fabry Disease
235
276
.
Mineyuki Mizuguchi, Yusuke Nakagawa, Kishin Inui, Wakana Katayama, Yurika Sawai, Ayaka Shimane, Ryota Kitakami, Takuya Okada, Yuko Nabeshima, Takeshi Yokoyama, Kayoko Kanamitsu, Shinsaku Nakagawa & Naoki Toyooka. (2022) Chlorinated Naringenin Analogues as Potential Inhibitors of Transthyretin Amyloidogenesis. Journal of Medicinal Chemistry 65:24, pages 16218-16233.
Crossref
Crossref
Mario Nuvolone, Maria Girelli & Giampaolo Merlini. (2022) Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy. International Journal of Molecular Sciences 23:24, pages 16145.
Crossref
Crossref
Mathew S. Maurer, Dia Smiley, Eli Simsolo, Fabrizio Remotti, Angela Bustamante, Sergio Teruya, Stephen Helmke, Andrew J. Einstein, Ronald Lehman, Jon T. Giles, Jeffery W. Kelly, Felix Tsai, William S. Blaner, Pierre‐Jacques Brun, Ron I. Riesenburger, James Kryzanski, Cindy Varga & Ayan R. Patel. (2022) Analysis of lumbar spine stenosis specimens for identification of amyloid. Journal of the American Geriatrics Society 70:12, pages 3538-3548.
Crossref
Crossref
Mathew S. Maurer. (2022) Overview of Current and Emerging Therapies for Amyloid Transthyretin Cardiomyopathy. The American Journal of Cardiology 185, pages S23-S34.
Crossref
Crossref
Julian Hartmann & Martin Zacharias. (2022) Analysis of amyloidogenic transthyretin mutations using continuum solvent free energy calculations. Proteins: Structure, Function, and Bioinformatics 90:12, pages 2080-2090.
Crossref
Crossref
Marcus A. C. Williams, Bairavi Shankar, Joban Vaishnav & Mark J. Ranek. (2022) Current and potential therapeutic strategies for transthyretin cardiac amyloidosis. Frontiers in Drug Discovery 2.
Crossref
Crossref
Caleb J. Hood, Nicholas S. Hendren, Rose Pedretti, Lori R. Roth, Lorena Saelices & Justin L. Grodin. (2022) Update on Disease-Specific Biomarkers in Transthyretin Cardiac Amyloidosis. Current Heart Failure Reports 19:5, pages 356-363.
Crossref
Crossref
Pranav Chandrashekar, Anish K. Desai & Barry H. Trachtenberg. (2021) Targeted treatments of AL and ATTR amyloidosis. Heart Failure Reviews 27:5, pages 1587-1603.
Crossref
Crossref
Rishabh Chaudhary, Mujeeba Rehman, Vipul Agarwal, Arjun Singh Kaushik & Vikas Mishra. 2022. Neurodegenerative Diseases: Multifactorial Degenerative Processes, Biomarkers and Therapeutic Approaches (First Edition). Neurodegenerative Diseases: Multifactorial Degenerative Processes, Biomarkers and Therapeutic Approaches (First Edition)
26
58
.
Chiara Sanguinetti, Marianna Minniti, Vanessa Susini, Laura Caponi, Giorgia Panichella, Vincenzo Castiglione, Alberto Aimo, Michele Emdin, Giuseppe Vergaro & Maria Franzini. (2022) The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism. Biomedicines 10:8, pages 1906.
Crossref
Crossref
Yves Ingenbleek. (2022) Plasma transthyretin is a nutritional biomarker in human morbidities. Frontiers of Medicine 16:4, pages 540-550.
Crossref
Crossref
Antonia Carroll, P James Dyck, Mamede de Carvalho, Marina Kennerson, Mary M Reilly, Matthew C Kiernan & Steve Vucic. (2022) Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. Journal of Neurology, Neurosurgery & Psychiatry 93:6, pages 668-678.
Crossref
Crossref
Fangyuan Zhang, Joshua Graham, Tianhua Zhai, Yanhong Liu & Zuyi Huang. (2022) Discovery of MurA Inhibitors as Novel Antimicrobials through an Integrated Computational and Experimental Approach. Antibiotics 11:4, pages 528.
Crossref
Crossref
Lily K. Stern & Jignesh Patel. (2022) Cardiac Amyloidosis Treatment. Methodist DeBakey Cardiovascular Journal 18:2, pages 59-72.
Crossref
Crossref
Makoto Hideshima, Yasuyoshi Kimura, César Aguirre, Keita Kakuda, Toshihide Takeuchi, Chi-Jing Choong, Junko Doi, Kei Nabekura, Keiichi Yamaguchi, Kichitaro Nakajima, Kousuke Baba, Seiichi Nagano, Yuji Goto, Yoshitaka Nagai, Hideki Mochizuki & Kensuke Ikenaka. (2022) Two-step screening method to identify α-synuclein aggregation inhibitors for Parkinson’s disease. Scientific Reports 12:1.
Crossref
Crossref
Monica Alcantara, Michelle M. Mezei, Steven K. Baker, Ari Breiner, Priya Dhawan, Amanda Fiander, Nowell M. Fine, Christopher Hahn, Hans D. Katzberg, Shahin Khayambashi, Rami Massie, Genevieve Matte, Brendan Putko, Zaeem Siddiqi, Diego Delgado & Vera Bril. (2021) Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy Management. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 49:1, pages 7-18.
Crossref
Crossref
Yukihiro Saito, Kazufumi Nakamura & Hiroshi Ito. (2021) Molecular Mechanisms of Cardiac Amyloidosis. International Journal of Molecular Sciences 23:1, pages 25.
Crossref
Crossref
Bin Zhong, Xianhua Huang, Yizhou Zheng, Xiaohua Guo & Longhuo Wu. (2021) The discovery and development of transthyretin amyloidogenesis inhibitors: what are the lessons?. Future Medicinal Chemistry 13:23, pages 2083-2105.
Crossref
Crossref
Laura Obici & Roberta Mussinelli. (2021) Current and Emerging Therapies for Hereditary Transthyretin Amyloidosis: Strides Towards a Brighter Future. Neurotherapeutics 18:4, pages 2286-2302.
Crossref
Crossref
Sebastián A. Esperante, Nathalia Varejāo, Francisca Pinheiro, Ricardo Sant'Anna, Juan Román Luque-Ortega, Carlos Alfonso, Valentina Sora, Elena Papaleo, Germán Rivas, David Reverter & Salvador Ventura. (2021) Disease-associated mutations impacting BC-loop flexibility trigger long-range transthyretin tetramer destabilization and aggregation. Journal of Biological Chemistry 297:3, pages 101039.
Crossref
Crossref
Robert Daniel Adam, Daniel Coriu, Andreea Jercan, Sorina Bădeliţă, Bogdan A. Popescu, Thibaud Damy & Ruxandra Jurcuţ. (2021) Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature. ESC Heart Failure 8:4, pages 2380-2396.
Crossref
Crossref
Emilia Czyżewska. (2021) Amyloidoses – pathogenesis, classification, diagnosis. Diagnostyka Laboratoryjna 56:4, pages 1-13.
Crossref
Crossref
Lily K. Stern & Michelle M. Kittleson. (2021) Updates in Cardiac Amyloidosis Diagnosis and Treatment. Current Oncology Reports 23:4.
Crossref
Crossref
Xin Jiang, Richard Labaudinière, Joel N. Buxbaum, Cecília MonteiroMarta Novais, Teresa CoelhoJeffery W. Kelly. (2021) A circulating, disease-specific, mechanism-linked biomarker for ATTR polyneuropathy diagnosis and response to therapy prediction. Proceedings of the National Academy of Sciences 118:9.
Crossref
Crossref
Meissane Benbrahim, Kelsey Norman, Vaishali Sanchorawala, Omar K Siddiqi & David Hughes. (2021) A review of novel agents and clinical considerations in patients with ATTR cardiac amyloidosis. Journal of Cardiovascular Pharmacology Publish Ahead of Print.
Crossref
Crossref
Darae Kim, Jin-Oh Choi & Eun-Seok Jeon. (2021) Tafamidis for Cardiac Transthyretin Amyloidosis. Cardiovascular Prevention and Pharmacotherapy 3:1, pages 1.
Crossref
Crossref
Qi Qin, Cuibai Wei, YueShan Piao, Fang Lian, Hao Wu, Aihong Zhou, Fen Wang, Xiumei Zuo, Yue Han, Jihui Lyu, Dongmei Guo & Jianping Jia. (2021) Current Review of Leptomeningeal Amyloidosis Associated With Transthyretin Mutations. The Neurologist 26:5, pages 189-195.
Crossref
Crossref
Evan T. Powers & Jeffery W. Kelly. 2021. Neurotherapeutics in the Era of Translational Medicine. Neurotherapeutics in the Era of Translational Medicine
65
103
.
Kevin M. Alexander, Matthew S. Maurer & Icilma V. Fergus. 2021. Cardiovascular Disease in Racial and Ethnic Minority Populations. Cardiovascular Disease in Racial and Ethnic Minority Populations
201
215
.
Vittorio D’Aguanno, Massimo Ralli, Marco Artico, Francesca Yoshie Russo, Alfonso Scarpa, Marco Fiore, Paola Tirassa, Cinzia Severini, Marco de Vincentiis & Antonio Greco. (2019) Systemic Amyloidosis: a Contemporary Overview. Clinical Reviews in Allergy & Immunology 59:3, pages 304-322.
Crossref
Crossref
Graham Lohrmann, Alexandra Pipilas, Roberta Mussinelli, Deepa M. Gopal, John L. Berk, Lawreen H. Connors, Nirupama Vellanki, Jennifer Hellawell, Omar K. Siddiqi, Jonathan Fox, Mathew S. Maurer & Frederick L. Ruberg. (2020) Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis. Journal of Cardiac Failure 26:9, pages 753-759.
Crossref
Crossref
Jay H. Park, Laura F. Cei & Keyur B. Shah. (2020) Disease-Modifying Pharmacological Therapies for Transthyretin Cardiac Amyloidosis. SN Comprehensive Clinical Medicine 2:9, pages 1607-1613.
Crossref
Crossref
Alice Nevone, Giampaolo Merlini & Mario Nuvolone. (2020) Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses. Frontiers in Pharmacology 11.
Crossref
Crossref
Jeffery W. Kelly. (2020) Pharmacologic Approaches for Adapting Proteostasis in the Secretory Pathway to Ameliorate Protein Conformational Diseases. Cold Spring Harbor Perspectives in Biology 12:5, pages a034108.
Crossref
Crossref
Tahir Nazir & Mahmud Nuffati. (2020) Cardiac amyloidosis—an underdiagnosed cause of heart failure in the elderly. Journal of the Saudi Heart Association 32:1.
Crossref
Crossref
Ridwan Babatunde Ibrahim, Ssu-Yu Yeh, Kon-Ping Lin, Frans Ricardo, Tsyr-Yan Yu, Chih-Chiang Chan, Jin-Wu Tsai & Yo-Tsen Liu. (2019) Cellular secretion and cytotoxicity of transthyretin mutant proteins underlie late-onset amyloidosis and neurodegeneration. Cellular and Molecular Life Sciences 77:7, pages 1421-1434.
Crossref
Crossref
Sandra Ihne, Caroline Morbach, Claudia Sommer, Andreas Geier, Stefan Knop & Stefan Störk. (2020) Amyloidosis—the Diagnosis and Treatment of an Underdiagnosed Disease. Deutsches Ärzteblatt international.
Crossref
Crossref
Elissa Driggin & Mathew S. Maurer. (2019) The quintessential form of diastolic heart failure in older adults: Wild type transthyretin cardiac amyloidosis. Clinical Cardiology 43:2, pages 171-178.
Crossref
Crossref
Joohee Lee, Kihyun Kim, Jin-Oh Choi, Seok Jin Kim, Eun-Seok Jeon & Joon Young Choi. (2020) 99mTc-DPD scintigraphy and SPECT/CT in patients with AL and ATTR type amyloidosis. Medicine 99:4, pages e18905.
Crossref
Crossref
Jaime Santos, Valentín Iglesias & Salvador Ventura. 2020. Oligomerization in Health and Disease: From Enzymes to G Protein-Coupled Receptors. Oligomerization in Health and Disease: From Enzymes to G Protein-Coupled Receptors
43
83
.
Maximilian L. Müller, Javed Butler & Bettina Heidecker. (2020) Emerging therapies in transthyretin amyloidosis – a new wave of hope after years of stagnancy?. European Journal of Heart Failure 22:1, pages 39-53.
Crossref
Crossref
Fredrick Nwude Eze, Kornkanok Ingkaninan & Porntip Prapunpoj. (2019) Transthyretin Anti-Amyloidogenic and Fibril Disrupting Activities of Bacopa monnieri (L.) Wettst (Brahmi) Extract. Biomolecules 9:12, pages 845.
Crossref
Crossref
Michele Emdin, Alberto Aimo, Claudio Rapezzi, Marianna Fontana, Federico Perfetto, Petar M Seferović, Andrea Barison, Vincenzo Castiglione, Giuseppe Vergaro, Alberto Giannoni, Claudio Passino & Giampaolo Merlini. (2019) Treatment of cardiac transthyretin amyloidosis: an update. European Heart Journal 40:45, pages 3699-3706.
Crossref
Crossref
Jose-Alberto Palma, Alejandra Gonzalez-Duarte & Horacio Kaufmann. (2019) Orthostatic hypotension in hereditary transthyretin amyloidosis: epidemiology, diagnosis and management. Clinical Autonomic Research 29:S1, pages 33-44.
Crossref
Crossref
Morie A. Gertz, Michelle L. Mauermann, Martha Grogan & Teresa Coelho. (2019) Advances in the treatment of hereditary transthyretin amyloidosis: A review. Brain and Behavior 9:9.
Crossref
Crossref
George H. Sack Jr.. 2019. Amyloid Diseases. Amyloid Diseases.
Kevin M. Alexander, Alessandro Evangelisti & Ronald M. Witteles. (2019) Emerging Therapies for Transthyretin Cardiac Amyloidosis. Current Treatment Options in Cardiovascular Medicine 21:8.
Crossref
Crossref
Mitsuharu Ueda, Masamitsu Okada, Mineyuki Mizuguchi, Barbara Kluve-Beckerman, Kyosuke Kanenawa, Aito Isoguchi, Yohei Misumi, Masayoshi Tasaki, Akihiko Ueda, Akinori Kanai, Ryoko Sasaki, Teruaki Masuda, Yasuteru Inoue, Toshiya Nomura, Satoru Shinriki, Tsuyoshi Shuto, Hirofumi Kai, Taro Yamashita, Hirotaka Matsui, Merrill D. Benson & Yukio Ando. (2019) A cell-based high-throughput screening method to directly examine transthyretin amyloid fibril formation at neutral pH. Journal of Biological Chemistry 294:29, pages 11259-11275.
Crossref
Crossref
Ioana M. Ilie & Amedeo Caflisch. (2019) Simulation Studies of Amyloidogenic Polypeptides and Their Aggregates. Chemical Reviews 119:12, pages 6956-6993.
Crossref
Crossref
Kathleen W. Zhang, Keith E. Stockerl-Goldstein & Daniel J. Lenihan. (2019) Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis. JACC: Basic to Translational Science 4:3, pages 438-448.
Crossref
Crossref
Gareth J. Morgan, Nicholas L. YanDavid E. MortensonEnrico RennellaJoshua M. BlundonRyan M. GwinChung-Yon LinRobyn L. StanfieldSteven J. BrownHugh RosenTimothy P. SpicerVirneliz Fernandez-VegaGiampaolo MerliniLewis E. KayIan A. Wilson & Jeffery W. Kelly. (2019) Stabilization of amyloidogenic immunoglobulin light chains by small molecules. Proceedings of the National Academy of Sciences 116:17, pages 8360-8369.
Crossref
Crossref
Nelson Ferreira, Maria Saraiva & Maria Almeida. (2019) Uncovering the Neuroprotective Mechanisms of Curcumin on Transthyretin Amyloidosis. International Journal of Molecular Sciences 20:6, pages 1287.
Crossref
Crossref
Massimiliano Lorenzini & Perry M Elliott. (2019) Tafamidis for the treatment of transthyretin amyloidosis. Future Cardiology 15:2, pages 53-61.
Crossref
Crossref
Arnt V Kristen, Senda Ajroud-Driss, Isabel Conceição, Peter Gorevic, Theodoros Kyriakides & Laura Obici. (2019) Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. Neurodegenerative Disease Management 9:1, pages 5-23.
Crossref
Crossref
Yinan ZhaoYanguo XinZhuyin SongZhiyi HeWenyu Hu. (2019) Tafamidis, a Noninvasive Therapy for Delaying Transthyretin Familial Amyloid Polyneuropathy: Systematic Review and Meta-Analysis. Journal of Clinical Neurology 15:1, pages 108.
Crossref
Crossref
Chi-Chao Chao, Hung-Wei Kan, Ti-Yen Yeh, Ya-Yin Cheng & Sung-Tsang Hsieh. 2019. Small Fiber Neuropathy and Related Syndromes: Pain and Neurodegeneration. Small Fiber Neuropathy and Related Syndromes: Pain and Neurodegeneration
83
97
.
Tamer Rezk & Philip N. Hawkins. 2019. Textbook of Autoinflammation. Textbook of Autoinflammation
267
289
.
Yukimoto Tsuda, Kunitoshi Yamanaka, Risa Toyoshima, Mitsuharu Ueda, Teruaki Masuda, Yohei Misumi, Teru Ogura & Yukio Ando. (2018) Development of transgenic Caenorhabditis elegans expressing human transthyretin as a model for drug screening. Scientific Reports 8:1.
Crossref
Crossref
Yoshiki Sekijima, Mitsuharu Ueda, Haruki Koike, Sonoko Misawa, Tomonori Ishii & Yukio Ando. (2018) Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Orphanet Journal of Rare Diseases 13:1.
Crossref
Crossref
Rachelle Morgenstern, Randy Yeh, Adam Castano, Mathew S. Maurer & Sabahat Bokhari. (2017) 18Fluorine sodium fluoride positron emission tomography, a potential biomarker of transthyretin cardiac amyloidosis. Journal of Nuclear Cardiology 25:5, pages 1559-1567.
Crossref
Crossref
Mark Miller, Arindom Pal, Wabel Albusairi, Hyun Joo, Beverly Pappas, Md Tariqul Haque Tuhin, Dengpan Liang, Raghavendra Jampala, Fang Liu, Jared Khan, Marjon Faaij, Miki Park, William Chan, Isabella Graef, Robert Zamboni, Neil Kumar, Jonathan Fox, Uma Sinha & Mamoun Alhamadsheh. (2018) Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis. Journal of Medicinal Chemistry 61:17, pages 7862-7876.
Crossref
Crossref
Elena S. KlimtchukTatiana ProkaevaNicholas M. FrameHassan A. AbdullahiBrian SpencerSurendra DasariHaili CuiJohn L. BerkPaul J. Kurtin, Lawreen H. ConnorsOlga Gursky. (2018) Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease. Proceedings of the National Academy of Sciences 115:28.
Crossref
Crossref
Merrill D. BensonMárcia Waddington-CruzJohn L. BerkMichael PolydefkisPeter J. DyckAnnabel K. WangViolaine Planté-BordeneuveFabio A. BarrosoGiampaolo MerliniLaura ObiciMorton ScheinbergThomas H. BrannaganIIIIIIWilliam J. LitchyCarol WhelanBrian M. DrachmanDavid AdamsStephen B. HeitnerIsabel ConceiçãoHartmut H. SchmidtGiuseppe VitaJosep M. CampistolJosep GamezPeter D. GorevicEdward GaneAmil M. ShahScott D. SolomonBrett P. MoniaSteven G. HughesT. Jesse KwohBradley W. McEvoyShiangtung W. JungBrenda F. BakerElizabeth J. AckermannMorie A. GertzTeresa Coelho. (2018) Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. New England Journal of Medicine 379:1, pages 22-31.
Crossref
Crossref
Scot Walker. (2018) New Medications in the Treatment of Hereditary Transthyretin Amyloidosis. Hospital Pharmacy 53:4, pages 236-238.
Crossref
Crossref
Morie A. Gertz. (2018) Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018. Blood Cancer Journal 8:5.
Crossref
Crossref
Hannah RosenblumAdam CastanoJulissa AlvarezJeff GoldsmithStephen HelmkeMathew S. Maurer. (2018) TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac Amyloidosis. Circulation: Heart Failure 11:4.
Crossref
Crossref
Violaine Plante-Bordeneuve. (2017) Transthyretin familial amyloid polyneuropathy: an update. Journal of Neurology 265:4, pages 976-983.
Crossref
Crossref
I. V. Demko, L. I. Pelinovskaya, Irina A. Soloveva, A. Yu. Kraposhina, N. V. Gordeeva & V. A. Mosina. (2018) Primary cardiac amyloidosis.. Clinical Medicine (Russian Journal) 95:11, pages 971-976.
Crossref
Crossref
Todd D Levine. (2018) Small Fiber Neuropathy: Disease Classification Beyond Pain and Burning. Journal of Central Nervous System Disease 10, pages 117957351877170.
Crossref
Crossref
J.A. Cowgill & J.N. WightJr.Jr.. 2018. Encyclopedia of Cardiovascular Research and Medicine. Encyclopedia of Cardiovascular Research and Medicine
242
256
.
J.N. WightJrJr. 2018. Reference Module in Biomedical Sciences. Reference Module in Biomedical Sciences.
Ayeman Amanullah, Arun Upadhyay, Vibhuti Joshi, Ribhav Mishra, Nihar Ranjan Jana & Amit Mishra. (2017) Progressing neurobiological strategies against proteostasis failure: Challenges in neurodegeneration. Progress in Neurobiology 159, pages 1-38.
Crossref
Crossref
Kevin M. Alexander, Avinainder Singh & Rodney H. Falk. (2017) Novel pharmacotherapies for cardiac amyloidosis. Pharmacology & Therapeutics 180, pages 129-138.
Crossref
Crossref
Stephen Connelly, David E. Mortenson, Sungwook Choi, Ian A. Wilson, Evan T. Powers, Jeffery W. Kelly & Steven M. Johnson. (2017) Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors. Bioorganic & Medicinal Chemistry Letters 27:15, pages 3441-3449.
Crossref
Crossref
Jeannine Hoepfner, Mandy Kleinsorge, Oliver Papp, Susanne Alfken, Robin Heiringhoff, Andreas Pich, Vanessa Sauer, Andree Zibert, Gudrun Göhring, Hartmut Schmidt, Malte Sgodda & Tobias Cantz. (2017) In vitro modelling of familial amyloidotic polyneuropathy allows quantitative detection of transthyretin amyloid fibril-like structures in hepatic derivatives of patient-specific induced pluripotent stem cells. Biological Chemistry 398:8, pages 939-954.
Crossref
Crossref
Ralph C. Budd & David C. Seldin. 2017. Kelley and Firestein's Textbook of Rheumatology. Kelley and Firestein's Textbook of Rheumatology
1973
1982
.
Danielle L. Brunjes, Adam Castano, Autumn Clemons, Jonah Rubin & Mathew S. Maurer. (2016) Transthyretin Cardiac Amyloidosis in Older Americans. Journal of Cardiac Failure 22:12, pages 996-1003.
Crossref
Crossref
Philippe Kerschen & Violaine Planté-Bordeneuve. (2016) Current and Future Treatment Approaches in Transthyretin Familial Amyloid Polyneuropathy. Current Treatment Options in Neurology 18:12.
Crossref
Crossref
Rajshekhar Chakraborty, Eli Muchtar & Morie A. Gertz. (2016) Newer Therapies for Amyloid Cardiomyopathy. Current Heart Failure Reports 13:5, pages 237-246.
Crossref
Crossref
Cristina A. Teixeira, Maria do Rosário Almeida & Maria João Saraiva. (2016)
Impairment of autophagy by TTR V30M aggregates:
in vivo
reversal by TUDCA and curcumin
. Clinical Science 130:18, pages 1665-1675.
Crossref
Crossref
M. Ankarcrona, B. Winblad, C. Monteiro, C. Fearns, E. T. Powers, J. Johansson, G. T. Westermark, J. Presto, B.-G. Ericzon & J. W. Kelly. (2016) Current and future treatment of amyloid diseases. Journal of Internal Medicine 280:2, pages 177-202.
Crossref
Crossref
Raúl I Campos, Xiongyu Wu, Mathias Elgland, Peter Konradsson & Per Hammarström. (2016)
Novel
trans
-Stilbene-based Fluorophores as Probes for Spectral Discrimination of Native and Protofibrillar Transthyretin
. ACS Chemical Neuroscience 7:7, pages 924-940.
Crossref
Crossref
Marc J. Semigran. (2016) Transthyretin Amyloidosis. Journal of the American College of Cardiology 68:2, pages 173-175.
Crossref
Crossref
Aleksandra Baranczak & Jeffery W Kelly. (2016) A current pharmacologic agent versus the promise of next generation therapeutics to ameliorate protein misfolding and/or aggregation diseases. Current Opinion in Chemical Biology 32, pages 10-21.
Crossref
Crossref
Ashutosh D Wechalekar, Julian D Gillmore & Philip N Hawkins. (2016) Systemic amyloidosis. The Lancet 387:10038, pages 2641-2654.
Crossref
Crossref
Teresa Coelho, Giampaolo Merlini, Christine E. Bulawa, James A. Fleming, Daniel P. Judge, Jeffery W. Kelly, Mathew S. Maurer, Violaine Planté-Bordeneuve, Richard Labaudinière, Rajiv Mundayat, Steve Riley, Ilise Lombardo & Pedro Huertas. (2016) Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. Neurology and Therapy 5:1, pages 1-25.
Crossref
Crossref
Irina Iakovleva, Afshan Begum, Kristoffer Brännström, Alexandra Wijsekera, Lina Nilsson, Jin Zhang, Patrik L. Andersson, A. Elisabeth Sauer-Eriksson & Anders Olofsson. (2016) Tetrabromobisphenol A Is an Efficient Stabilizer of the Transthyretin Tetramer. PLOS ONE 11:4, pages e0153529.
Crossref
Crossref
Ricardo Sant'Anna, Pablo Gallego, Lei Z. Robinson, Alda Pereira-Henriques, Nelson Ferreira, Francisca Pinheiro, Sebastian Esperante, Irantzu Pallares, Oscar Huertas, Maria Rosário Almeida, Natàlia Reixach, Raul Insa, Adrian Velazquez-Campoy, David Reverter, Núria Reig & Salvador Ventura. (2016) Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nature Communications 7:1.
Crossref
Crossref
David Adams, Ole B. Suhr, Ernst Hund, Laura Obici, Ivailo Tournev, Josep M. Campistol, Michel S. Slama, Bouke P. Hazenberg & Teresa Coelho. (2016) First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Current Opinion in Neurology 29:Supplement 1, pages S14-S26.
Crossref
Crossref
Morie A. Gertz, Merrill D. Benson, Peter J. Dyck, Martha Grogan, Terresa Coelho, Marcia Cruz, John L. Berk, Violaine Plante-Bordeneuve, Hartmut H.J. Schmidt & Giampaolo Merlini. (2015) Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis. Journal of the American College of Cardiology 66:21, pages 2451-2466.
Crossref
Crossref
Yvonne S. Eisele, Cecilia Monteiro, Colleen Fearns, Sandra E. Encalada, R. Luke Wiseman, Evan T. Powers & Jeffery W. Kelly. (2015) Targeting protein aggregation for the treatment of degenerative diseases. Nature Reviews Drug Discovery 14:11, pages 759-780.
Crossref
Crossref
Yoshiki Sekijima. (2015) Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. Journal of Neurology, Neurosurgery & Psychiatry 86:9, pages 1036-1043.
Crossref
Crossref
Irina Iakovleva, Kristoffer Brännström, Lina Nilsson, Anna L. Gharibyan, Afshan Begum, Intissar Anan, Malin Walfridsson, A. Elisabeth Sauer-Eriksson & Anders Olofsson. (2015) Enthalpic Forces Correlate with the Selectivity of Transthyretin-Stabilizing Ligands in Human Plasma. Journal of Medicinal Chemistry 58:16, pages 6507-6515.
Crossref
Crossref
Simon Dubrey, Elizabeth Ackermann & Julian Gillmore. (2015) The transthyretin amyloidoses: advances in therapy. Postgraduate Medical Journal 91:1078, pages 439-448.
Crossref
Crossref
Yanshuang Mu, Shoude Jin, Jingling Shen, Aki Sugano, Yutaka Takaoka, Lixia Qiang, Bruno P. Imbimbo, Ken-ichi Yamamura & Zhenghua Li. (2015) CHF5074 (CSP‐1103) stabilizes human transthyretin in mice humanized at the transthyretin and retinol‐binding protein loci. FEBS Letters 589:7, pages 849-856.
Crossref
Crossref
Rabya H. Sayed, Philip N. Hawkins & Helen J. Lachmann. (2015) Emerging treatments for amyloidosis. Kidney International 87:3, pages 516-526.
Crossref
Crossref
Adam Castaño, Brian M. Drachman, Daniel Judge & Mathew S. Maurer. (2014) Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Failure Reviews 20:2, pages 163-178.
Crossref
Crossref
Gunilla T. WestermarkMarcus FändrichPer Westermark. (2015) AA Amyloidosis: Pathogenesis and Targeted Therapy. Annual Review of Pathology: Mechanisms of Disease 10:1, pages 321-344.
Crossref
Crossref
Adam J. Loavenbruck, JaNean K. Engelstad & Christopher J. Klein. 2015. Amyloid and Related Disorders. Amyloid and Related Disorders
437
450
.
Richard Labaudinière. 2014. Orphan Drugs and Rare Diseases. Orphan Drugs and Rare Diseases
202
229
.
Simon W Dubrey & Sarah Ghonim. (2014) Amyloid heart disease (part 2): Management and specific treatments. British Journal of Cardiac Nursing 9:7, pages 330-335.
Crossref
Crossref
Y. Sekijima. (2014) Recent progress in the understanding and treatment of transthyretin amyloidosis. Journal of Clinical Pharmacy and Therapeutics 39:3, pages 225-233.
Crossref
Crossref
António O.L. Évora, Ricardo A.E. Castro, Teresa M.R. Maria, M. Ramos Silva, J.H. ter Horst, João Canotilho & M. Ermelinda S. Eusébio. (2014) A thermodynamic based approach on the investigation of a diflunisal pharmaceutical co-crystal with improved intrinsic dissolution rate. International Journal of Pharmaceutics 466:1-2, pages 68-75.
Crossref
Crossref
Irit Rappley, Cecília Monteiro, Marta Novais, Aleksandra Baranczak, Gregory Solis, R. Luke Wiseman, Stephen Helmke, Mathew S. Maurer, Teresa Coelho, Evan T. Powers & Jeffery W. Kelly. (2014) Quantification of Transthyretin Kinetic Stability in Human Plasma Using Subunit Exchange. Biochemistry 53:12, pages 1993-2006.
Crossref
Crossref
Mazen Hanna. (2014) Novel Drugs Targeting Transthyretin Amyloidosis. Current Heart Failure Reports 11:1, pages 50-57.
Crossref
Crossref
Sabahat Bokhari, Reehan Shahzad, Adam Castaño & Mathew S. Maurer. (2013) Nuclear imaging modalities for cardiac amyloidosis. Journal of Nuclear Cardiology 21:1, pages 175-184.
Crossref
Crossref
Julie S. ValastyanSusan Lindquist. (2014) Mechanisms of protein-folding diseases at a glance. Disease Models & Mechanisms 7:1, pages 9-14.
Crossref
Crossref
Eul Hyun Suh, Yu Liu, Stephen Connelly, Joseph C. Genereux, Ian A. Wilson & Jeffery W. Kelly. (2013) Stilbene Vinyl Sulfonamides as Fluorogenic Sensors of and Traceless Covalent Kinetic Stabilizers of Transthyretin That Prevent Amyloidogenesis. Journal of the American Chemical Society 135:47, pages 17869-17880.
Crossref
Crossref
Amy Leung, Shirley K. Nah, Whitney Reid, Atsushi Ebata, Clarissa M. Koch, Stefano Monti, Joseph C. Genereux, R. Luke Wiseman, Benjamin Wolozin, Lawreen H. Connors, John L. Berk, David C. Seldin, Gustavo Mostoslavsky, Darrell N. Kotton & George J. Murphy. (2013) Induced Pluripotent Stem Cell Modeling of Multisystemic, Hereditary Transthyretin Amyloidosis. Stem Cell Reports 1:5, pages 451-463.
Crossref
Crossref
Keiko Tanaka, Yoshiki Sekijima, Kunihiro Yoshida, Mariko Tamai, Tomoki Kosho, Akihiro Sakurai, Keiko Wakui, Shu-ichi Ikeda & Yoshimitsu Fukushima. (2013) Follow-up nationwide survey on predictive genetic testing for late-onset hereditary neurological diseases in Japan. Journal of Human Genetics 58:8, pages 560-563.
Crossref
Crossref
Sravan C. PenchalaStephen Connelly, Yu WangMiki S. ParkLei Zhao, Aleksandra Baranczak, Irit Rappley, Hannes Vogel, Michaela Liedtke, Ronald M. Witteles, Evan T. Powers, Natàlia Reixach, William K. ChanIan A. Wilson, Jeffery W. Kelly, Isabella A. Graef & Mamoun M. Alhamadsheh. (2013) AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proceedings of the National Academy of Sciences 110:24, pages 9992-9997.
Crossref
Crossref
Pablo Taboada, Silvia Barbosa, Josué Juárez, Manuel‐Alatorre Meda & Víctor Mosquera. 2013. Proteins in Solution and at Interfaces. Proteins in Solution and at Interfaces
233
282
.
Colleen Fearns, Stephen Connelly, Evan T. Powers & Jeffery W. Kelly. 2013. Amyloid Fibrils and Prefibrillar Aggregates. Amyloid Fibrils and Prefibrillar Aggregates
373
394
.
C. Rapezzi, C. C. Quarta, L. Obici, F. Perfetto, S. Longhi, F. Salvi, E. Biagini, M. Lorenzini, F. Grigioni, O. Leone, F. Cappelli, G. Palladini, P. Rimessi, A. Ferlini, G. Arpesella, A. D. Pinna, G. Merlini & S. Perlini. (2012) Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. European Heart Journal 34:7, pages 520-528.
Crossref
Crossref
Michal Fikrle, Tomáš Paleček, Petr Kuchynka, Eduard Němeček, Lenka Bauerová, Jan Straub & Romana Ryšavá. (2013) Cardiac amyloidosis: A comprehensive review. Cor et Vasa 55:1, pages e60-e75.
Crossref
Crossref
Kunihiro Yoshida, Takako Ohata, Kaori Muto, Atsushi Tsuchiya, Jinichi Sawada, Takanori Hazama, Shu-ichi Ikeda & Tatsushi Toda. (2013) Survey on the attitude toward genetic testing of neurologists certified by the Japanese Society of Neurology. Rinsho Shinkeigaku 53:5, pages 337-344.
Crossref
Crossref
Keiko Tanaka, Yoshiki Sekijima, Kunihiro Yoshida, Asako Mizuuchi, Hiromi Yamashita, Mariko Tamai, Shu-ichi Ikeda & Yoshimitsu Fukushima. (2013) Current status of the predictive genetic testing for hereditary neurological diseases in Shinshu University Hospital. Rinsho Shinkeigaku 53:3, pages 196-204.
Crossref
Crossref
Weipeng Li, Xiaowei Duan, Hong Yan & Hongxing Xin. (2013) Synthesis of 4H-1,4-oxazines as transthyretin amyloid fibril inhibitors. Organic & Biomolecular Chemistry 11:27, pages 4546.
Crossref
Crossref
David C. Seldin & Martha Skinner. 2013. Kelley's Textbook of Rheumatology. Kelley's Textbook of Rheumatology
1889
1897
.
Lori Krim Gavrin, Rajiah Aldrin Denny & Eddine Saiah. (2012) Small Molecules That Target Protein Misfolding. Journal of Medicinal Chemistry 55:24, pages 10823-10843.
Crossref
Crossref
Adam Castaño, Stephen Helmke, Julissa Alvarez, Susan Delisle & Mathew S. Maurer. (2012) Diflunisal for ATTR Cardiac Amyloidosis. Congestive Heart Failure 18:6, pages 315-319.
Crossref
Crossref
Susan C. Shin & Jessica Robinson‐Papp. (2012) Amyloid Neuropathies. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 79:6, pages 733-748.
Crossref
Crossref
Luísa Lobato & Ana Rocha. (2012) Transthyretin Amyloidosis and the Kidney. Clinical Journal of the American Society of Nephrology 7:8, pages 1337-1346.
Crossref
Crossref
Steven M. Johnson, Stephen Connelly, Colleen Fearns, Evan T. Powers & Jeffery W. Kelly. (2012) The Transthyretin Amyloidoses: From Delineating the Molecular Mechanism of Aggregation Linked to Pathology to a Regulatory-Agency-Approved Drug. Journal of Molecular Biology 421:2-3, pages 185-203.
Crossref
Crossref
S. W. Dubrey & R. L. Comenzo. (2012) Amyloid diseases of the heart: current and future therapies. QJM 105:7, pages 617-631.
Crossref
Crossref
Christine E. BulawaStephen ConnellyMichael DeVitLan WangCharlotte WeigelJames A. FlemingJeff PackmanEvan T. PowersR. Luke Wiseman, Theodore R. Foss, Ian A. WilsonJeffery W. Kelly & Richard Labaudinière. (2012) Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proceedings of the National Academy of Sciences 109:24, pages 9629-9634.
Crossref
Crossref
Fernando Martínez-Valle, Mercedes Gironella-Mesa & Roser Solans-Laqué. (2012) Avances en el tratamiento de la amiloidosis. Medicina Clínica 138:15, pages 667-672.
Crossref
Crossref
Sanjay M. Banypersad, James C. Moon, Carol Whelan, Philip N. Hawkins & Ashutosh D. Wechalekar. (2012) Updates in Cardiac Amyloidosis: A Review. Journal of the American Heart Association 1:2.
Crossref
Crossref
Kumar Dharmarajan & Mathew S. Maurer. (2012) Transthyretin Cardiac Amyloidoses in Older North Americans. Journal of the American Geriatrics Society 60:4, pages 765-774.
Crossref
Crossref
Adam J. Loavenbruck, Janean K. Engelstad & Christopher J. Klein. 2012. Amyloid and Related Disorders. Amyloid and Related Disorders
361
374
.
Estefania P. C. Azevedo, Humberto M. Pereira, Richard C. Garratt, Jeffery W. Kelly, Debora Foguel & Fernando L. Palhano. (2011) Dissecting the Structure, Thermodynamic Stability, and Aggregation Properties of the A25T Transthyretin (A25T-TTR) Variant Involved in Leptomeningeal Amyloidosis: Identifying Protein Partners That Co-Aggregate during A25T-TTR Fibrillogenesis in Cerebrospinal Fluid. Biochemistry 50:51, pages 11070-11083.
Crossref
Crossref
Hirofumi Jono, Takayuki Anno, Keiichi Motoyama, Yohei Misumi, Masayoshi Tasaki, Toshinori Oshima, Yoshimasa Mori, Mineyuki Mizuguchi, Mitsuharu Ueda, Makoto Shono, Konen Obayashi, Hidetoshi Arima & Yukio Ando. (2011) Cyclodextrin, a novel therapeutic tool for suppressing amyloidogenic transthyretin misfolding in transthyretin-related amyloidosis. Biochemical Journal 437:1, pages 35-42.
Crossref
Crossref
. (2011) Abstracts. Amyloid 18:Suppl. 1, pages 6-238.
Crossref
Crossref
Laura Lladó, Carme Baliellas, Carlos Casasnovas, Isidre Ferrer, Joan Fabregat, Emilio Ramos, Jose Castellote, Jaume Torras, Xavier Xiol & Antoni Rafecas. (2010) Risk of transmission of systemic transthyretin amyloidosis after domino liver transplantation. Liver Transplantation 16:12, pages 1386-1392.
Crossref
Crossref
Donald J. AbrahamAdriano D. Andricopulo, Rafael V.C. Guido, Daniela B.B. Trivella, Igor Polikarpov, Andrei Leitão & Carlos Montanari. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
685
724
.
Steven M. Johnson, Luke Wiseman, Johan F. Paulsson, Sungwook Choi, Evan T. Powers, Joel N. Buxbaum & Jeffery W. Kelly. 2010. Protein Misfolding Diseases. Protein Misfolding Diseases
967
1003
.
Steven R. Zeldenrust & Merrill D. Benson. 2010. Protein Misfolding Diseases. Protein Misfolding Diseases
795
815
.
Jose M. Sanchez-Ruiz. (2010) Protein kinetic stability. Biophysical Chemistry 148:1-3, pages 1-15.
Crossref
Crossref
Maria M. Picken. (2010) Amyloidosis—Where Are We Now and Where Are We Heading?. Archives of Pathology & Laboratory Medicine 134:4, pages 545-551.
Crossref
Crossref
Amber N. Murray, James P. Solomon, Ya-Juan Wang, William E. Balch & Jeffery W. Kelly. (2010) Discovery and characterization of a mammalian amyloid disaggregation activity. Protein Science 19:4, pages 836-846.
Crossref
Crossref
P. Christian Schulze & Mathew S. Maurer. (2010) Transthyretin Val30Met Mutation in an African American With Cardiac Amyloidosis. Congestive Heart Failure 16:2, pages 73-76.
Crossref
Crossref
Simon W Dubrey & Rodney H Falk. (2010) Amyloid heart disease. British Journal of Hospital Medicine 71:2, pages 76-82.
Crossref
Crossref
Masahide Yazaki, Ayako Suzuki, Shu-ichi Ikeda & Fuyuki Kametani. (2010) Biochemical analysis of deposited amyloid fibrils—Analysis of amyloid protein extracted from small biopsy samples. SEIBUTSU BUTSURI KAGAKU 54:1, pages 19-22.
Crossref
Crossref
Rodney H. Falk & Simon W. Dubrey. (2010) Amyloid Heart Disease. Progress in Cardiovascular Diseases 52:4, pages 347-361.
Crossref
Crossref
Luis Mauricio T.R. Lima, Vivian de Almeida Silva, Leonardo de Castro Palmieri, Maria Clara B.R. Oliveira, Débora Foguel & Igor Polikarpov. (2010) Identification of a novel ligand binding motif in the transthyretin channel. Bioorganic & Medicinal Chemistry 18:1, pages 100-110.
Crossref
Crossref
Rodney H. Falk & Simon W. Dubrey. 2010. Amyloidosis. Amyloidosis
107
128
.
Steven R. Zeldenrust. 2010. Amyloidosis. Amyloidosis
191
204
.
Douglas J. Martin, Edward G. Randles & Marina Ramirez-Alvarado. 2010. Amyloidosis. Amyloidosis
1
14
.
Philip B Dattilo. (2009) Familial (ATTR) amyloidosis misdiagnosed as the primary (AL) variant: a case report. Cases Journal 2:1.
Crossref
Crossref
Stavros Kounas & Perry M Elliott. 2009. Evidence‐Based Cardiology. Evidence‐Based Cardiology
808
822
.
Manuel Gómez-Bueno, Javier Segovia, Pablo García-Pavía, Juan M. Barceló, Isabel Krsnik, Víctor Sánchez-Turrión, Clara Salas & Luis Alonso-Pulpón. (2009) Cardiac Amyloidosis: The Importance of a Multidisciplinary Approach. Revista Española de Cardiología (English Edition) 62:6, pages 698-702.
Crossref
Crossref
Manuel Gómez-Bueno, Javier Segovia, Pablo García-Pavía, Juan M. Barceló, Isabel Krsnik, Víctor Sánchez-Turrión, Clara Salas & Luis Alonso-Pulpón. (2009) Amiloidosis cardiaca: la importancia del manejo multidisciplinario. Revista Española de Cardiología 62:6, pages 698-702.
Crossref
Crossref
Steven M. Johnson, Stephen Connelly, Ian A. Wilson & Jeffery W. Kelly. (2009) Toward Optimization of the Second Aryl Substructure Common to Transthyretin Amyloidogenesis Inhibitors Using Biochemical and Structural Studies. Journal of Medicinal Chemistry 52:4, pages 1115-1125.
Crossref
Crossref
Teresa Mairal, Joan Nieto, Marta Pinto, Maria Rosário Almeida, Luis Gales, Alfredo Ballesteros, José Barluenga, Juan J. Pérez, Jesús T. Vázquez, Nuria B. Centeno, Maria Joao Saraiva, Ana M. Damas, Antoni Planas, Gemma Arsequell & Gregorio Valencia. (2009) Iodine Atoms: A New Molecular Feature for the Design of Potent Transthyretin Fibrillogenesis Inhibitors. PLoS ONE 4:1, pages e4124.
Crossref
Crossref
Miguel Costas, David Rodríguez-Larrea, Leonardo De Maria, Torben V. Borchert, Armando Gómez-Puyou & Jose M. Sanchez-Ruiz. (2009) Between-Species Variation in the Kinetic Stability of TIM Proteins Linked to Solvation-Barrier Free Energies. Journal of Molecular Biology 385:3, pages 924-937.
Crossref
Crossref
Yukio Ando, Masaaki Nakamura, Mistuharu Ueda & Hirofumi Jono. 2009. Recent Advances in Transthyretin Evolution, Structure and Biological Functions. Recent Advances in Transthyretin Evolution, Structure and Biological Functions
215
238
.
John F. O'Brien & H. Robert BergenIIIIII. 2009. Mass Spectrometry of Proteins and Peptides. Mass Spectrometry of Proteins and Peptides
353
365
.
. (2008) Non-senile wild-type transthyretin systemic amyloidosis presenting as bilateral carpal tunnel syndrome. Journal of the Peripheral Nervous System 13:2, pages 148-150.
Crossref
Crossref
Kana Tojo, Yoshiki Sekijima, Kazuko Machida, Ayako Tsuchiya, Masahide Yazaki & Shu-Ichi Ikeda. (2008) Amyloidogenic transthyretin Val30Met homozygote showing unusually early-onset familial amyloid polyneuropathy. Muscle & Nerve 37:6, pages 796-803.
Crossref
Crossref
Yiwen Chen, Feng Ding, Huifen Nie, Adrian W. Serohijos, Shantanu Sharma, Kyle C. Wilcox, Shuangye Yin & Nikolay V. Dokholyan. (2008) Protein folding: Then and now. Archives of Biochemistry and Biophysics 469:1, pages 4-19.
Crossref
Crossref
David H.J. Bunka, Benjamin J. Mantle, Isobel J. Morten, Glenys A. Tennent, Sheena E. Radford & Peter G. Stockley. (2007) Production and Characterization of RNA Aptamers Specific for Amyloid Fibril Epitopes. Journal of Biological Chemistry 282:47, pages 34500-34509.
Crossref
Crossref
R. Luke Wiseman, Atanas Koulov, Evan Powers, Jeffery W. Kelly & William E. Balch. (2007) Protein energetics in maturation of the early secretory pathway. Current Opinion in Cell Biology 19:4, pages 359-367.
Crossref
Crossref
G Merlini. 2007. XIth International Symposium on Amyloidosis. XIth International Symposium on Amyloidosis
341
346
.
Displaying 200 of 202 citing articles. Use the download link below to view the full list of citing articles.
Download full citations list